Benchmark Co. analyst Robert Wasserman maintained a Buy rating on OmniAb (OABI – Research Report) today and set a price target of $8.00. The company’s shares closed yesterday at $4.43.
According to TipRanks, Wasserman is an analyst with an average return of -9.3% and a 26.67% success rate. Wasserman covers the Healthcare sector, focusing on stocks such as Halozyme, AbCellera Biologics, and Danaher.
Currently, the analyst consensus on OmniAb is a Strong Buy with an average price target of $9.83, a 121.90% upside from current levels. In a report released on November 10, H.C. Wainwright also reiterated a Buy rating on the stock with a $11.00 price target.
See today’s best-performing stocks on TipRanks >>
Based on OmniAb’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $6.95 million and a GAAP net loss of $14.73 million. In comparison, last year the company earned a revenue of $6.91 million and had a GAAP net loss of $12.6 million
Based on the recent corporate insider activity of 36 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of OABI in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
OmniAb (OABI) Company Description:
Avista Public Acquisition Corp II is a blank check company.
Read More on OABI:
